Sector
PharmaceuticalsOpen
₹314.55Prev. Close
₹315.9Turnover(Lac.)
₹10.45Day's High
₹318Day's Low
₹314.0552 Week's High
₹47952 Week's Low
₹279.85Book Value
₹121.76Face Value
₹10Mkt Cap (₹ Cr.)
691.65P/E
55.42EPS
5.7Divi. Yield
022 Jul 2024
12:00 AM
AGM
Announcement Date: 22 Jul, 2024
17 Oct 2024
12:00 AM
Board Meeting
Agenda : Audited Result
22 Jul 2024
12:00 AM
BookCloser
27 Nov 2023
12:00 AM
EGM
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 26.55 | 19.04 | 17.12 | 15.62 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 235.87 | 154.39 | 110.42 | 82.84 |
Net Worth | 262.42 | 173.43 | 127.54 | 98.46 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 94.73 | 82.98 | 53.07 | 44.17 |
yoy growth (%) | 14.17 | 56.34 | 20.16 | 7.14 |
Raw materials | -51.11 | -43.04 | -27.99 | -22.28 |
As % of sales | 53.95 | 51.87 | 52.75 | 50.45 |
Employee costs | -13.25 | -12.12 | -6.83 | -5.94 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 13.24 | 12.22 | 6.12 | 4.82 |
Depreciation | -8.05 | -7.07 | -4.4 | -3.38 |
Tax paid | -2.55 | -2.6 | -2.29 | -1.44 |
Working capital | -6.96 | -4.37 | -1.06 | 8.98 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.17 | 56.34 | 20.16 | 7.14 |
Op profit growth | 15.68 | 55.25 | 23.85 | 21.84 |
EBIT growth | 8.59 | 66.22 | 16.01 | 29.13 |
Net profit growth | 11.11 | 152.25 | 12.91 | 52.31 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Gross Sales | 153.35 | 133.36 | 128.23 | 94.74 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 153.35 | 133.36 | 128.23 | 94.74 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 3.18 | 4.67 | 2.17 | 1.18 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,813.45 | 157.5 | 4,34,195.65 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,096.2 | 88.09 | 1,61,829.65 | 518 | 0.49 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,498.25 | 28.59 | 1,21,053.04 | 1,178.16 | 0.87 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,361.5 | 69.57 | 1,13,812.4 | 460 | 0.83 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,615.5 | 52.35 | 1,04,937.42 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sanjay S Shah.
Joint Managing Director
Aarsh S Shah
Whole-time Director
Ritaben S Shah
Independent Non Exe. Director
Shailesh B Patel
Independent Non Exe. Director
Prashant C Srivastav
Independent Non Exe. Director
Hemendrakumar C Shah
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Sakar Healthcare Ltd
Summary
Sakar Healthcare Limited was incorporated as a Private Limited Company under the name Sakar Healthcare Private Limited on 26th March 2004. Subsequently, the Company was converted into Public Limited Company on March 27, 2015 and the name of the Company was changed to Sakar Healthcare Limited. The Company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah.The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections and Oral Solid Dossages. It manufactures and markets pharmaceutical formulations relating to analgesics, anti coagulants, anti malarial, anti spasmodic, antianemics, antibiotics, anti-emetics, anti-histamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.The Company operates as contract development and manufacturing organisation (CDMO), being the EU GMP approved CMO for leading multinational pharmaceutical companies.Their 4 manufacturing facilities located at Changodar, Ahmedabad, Gujarat. have been approved by various international regulatory authorities and certified by ISO 9001:2008 (BVQI), WHO-GMP, CGMP & National Drug Authority, and it has obtained certain drug specific registrations from the relevant authorities in countries such as Uganda, Kenya, Yemen, Ethiopia, Congo, Ghana, Zimbabwe, Namibia, Nigeria, Cote divoire.In 2005, the Company started co
Read More
What is the Sakar Healthcare Ltd share price today?
The Sakar Healthcare Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹318 today.
What is the Market Cap of Sakar Healthcare Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sakar Healthcare Ltd is ₹691.65 Cr. as of 06 Dec ‘24
What is the PE and PB ratio of Sakar Healthcare Ltd?
The PE and PB ratios of Sakar Healthcare Ltd is 55.42 and 2.55 as of 06 Dec ‘24
What is the 52 Week High and Low of Sakar Healthcare Ltd?
The 52-week high/low is the highest and lowest price at which a Sakar Healthcare Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sakar Healthcare Ltd is ₹279.85 and ₹479 as of 06 Dec ‘24
What is the CAGR of Sakar Healthcare Ltd?
Sakar Healthcare Ltd's CAGR for 5 Years at 44.04%, 3 Years at 31.46%, 1 Year at -16.65%, 6 Month at 2.90%, 3 Month at -1.59% and 1 Month at -2.14%.
What is the shareholding pattern of Sakar Healthcare Ltd?
The shareholding pattern of Sakar Healthcare Ltd is as follows:
Promoters - 53.15 %
Institutions - 24.04 %
Public - 22.80 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
